Cefpodoxime proxetil

Caitlin Soto, PharmD, BCIDP, Edina Avdic, Pharm.D., BCPS

INDICATIONS

INDICATIONS

INDICATIONS

FDA

FDA

FDA

  • Approved for the following mild-moderate bacterial infections:
    • Upper respiratory tract infections, including acute otitis media, pharyngitis/tonsillitis,acute exacerbation of chronic bronchitis (AECB), and acute bacterial maxillary sinusitis
    • Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC)
    • Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
    • Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
    • Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae
    • Uncomplicated gonorrhea (no longer recommended per CDC guideline)

NON-FDA APPROVED USES

NON-FDA APPROVED USES

NON-FDA APPROVED USES

  • Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
  • Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
    • IDSA 2025 complicated UTI Guideline recommends:
      • Complicated UTI (including acute pyelonephritis), avoid antibiotics to which the patient has had a resistant pathogen isolated from the urine previously
      • For pylenephritis, including sepsis/shock, once clinically improved, can have an early transition from parenteral to oral therapy if such an.

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2026 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.